The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member
Formerly named Institut Albert Bonniot, the Institute for Advanced Biosciences is large joint center (19 teams, 5 platforms) of INSERM, CNRS and University Grenoble-Alpes. Its scientific strategy focuses on how environmental constraints (micro- and macro-) shape (epi)genomes and tissues during development and diseases. A central theme shared across teams is respiratory health, covering air quality and impact of air pollution, chronic respiratory diseases (asthma, COPD) and lung cancer. IAB deploys a multidisciplinary expertise scientific from molecules to populations and encompassing genetics, epigenetics/signaling through chromatin, cell-matrix interactions, cell signaling, host-parasite interactions, immunology and environmental epidemiology.
Asthma\Cell biology\Epigenetics\Lung cancer\Molecular biology
Global fellowships (return phase only)\ European fellowships
IAB (300 researchers and clinicians) is located next to Grenoble University Hospital. It offers shared platforms covering a translational continuum from molecules to biomarkers and targets for clinical value. These platforms include: medical epigenetics (EpiMED), protein engineering (IngeProt), advanced cell imaging (MicroCell), metabolomics (GEMELI), preclinical animal models (Optimal). IAB researchers have constituted unique resources on respiratory health, including environmental cohorts (exposome studies, PI R SLAMA) and lung tumor and tissue banks and databases (PI: E BRAMBILLA, n=4000). IAB has a partnership with EMBL Grenoble on structural biology, supporting research on innovative drug targets.
Of 19 IAB groups, 5 (60 staff) are engaged in research on respiratory health: (1) S. KHOCHBIN (epigenetic reprograming in COPD/lung cancer); (2) B. EYMIN (lung cancer spliceosome as drug target in lung cancer); (3) JL. COLL (nanovectors for cancer therapy); (4) P. HAINAUT/E. BRAMBILLA (histomolecular classification of lung cancers, TP53 mutations) and (5) R. SLAMA/V. SIROUX (asthma in children, air pollution).
Funding include (1) H2020 ATHLETE (SIROUX, SLAMA, 12 M€), MSD-Avenir ERiCAN (HAINAUT, 2.1 M€), LIFE (Respiratory health trajectories, HAINAUT/KHOCHBIN/SIROUX, 2 M€), EIT-HEALTH PAPHOD AND PATIENTMINER (HAINAUT, total 1 M€), Canc’Air (ARC, Air pollution and epigenome), LEPEULE/KHOCHBIN (0.5M€).
IAB is operating within a dense ecosystem of innovation and value creation, considered as one of the most successful at national level. The main partners of IAB are Floralis (the innovation subsidiary of UGA), SATT Linksium, Inserm Transfer and Cancéropole CLARA. In addition, IAB has a technology transfer manager who supports researchers for patents registration and startup creation. A total of 7 start-ups and 39 patents have been developed in 2015-20.
IAB host researchers from 27 nationalities on all continents (20% of the staff). IAB develops an international strategy for attracting and promoting new talents, either though recruitment, mobility or promotion (call for new leaders in 2018-19 for example). IAB conducts training through research and hands-on practice and offers mentorship towards progression to independence. International mobility, multiculturality, equal opportunity and the values of laicity are actively promoted. IAB is open to all nationalities and operates in both French and English languages.
Yes